These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22136510)

  • 21. Is [symbol: see text] Yasmin a "truly different" pill?
    Drug Ther Bull; 2002 Aug; 40(8):57-9. PubMed ID: 12216337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benefits and risks of oral contraceptives.
    Drife J
    Adv Contracept; 1990 Dec; 6 Suppl():15-25. PubMed ID: 2291444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being.
    Boschitsch E; Skarabis H; Wuttke W; Heithecker R
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():34-40. PubMed ID: 11246600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome.
    Kriplani A; Periyasamy AJ; Agarwal N; Kulshrestha V; Kumar A; Ammini AC
    Contraception; 2010 Aug; 82(2):139-46. PubMed ID: 20654754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ethinylestradiol + norelgestromin: new preparation. Transdermal contraception: no tangible progress.
    Prescrire Int; 2004 Aug; 13(72):123-6. PubMed ID: 15532134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drospirenone: high risk of venous thrombosis.
    Prescrire Int; 2011 Feb; 20(113):43-5. PubMed ID: 21488592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ongoing or previous mental disorders predispose to adverse mood reporting during combined oral contraceptive use.
    Bengtsdotter H; Lundin C; Gemzell Danielsson K; Bixo M; Baumgart J; Marions L; Brynhildsen J; Malmborg A; Lindh I; Sundström Poromaa I
    Eur J Contracept Reprod Health Care; 2018 Feb; 23(1):45-51. PubMed ID: 29323577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial.
    Koltun W; Lucky AW; Thiboutot D; Niknian M; Sampson-Landers C; Korner P; Marr J
    Contraception; 2008 Apr; 77(4):249-56. PubMed ID: 18342647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception.
    Borges LE; Andrade RP; Aldrighi JM; Guazelli C; Yazlle ME; Isaia CF; Petracco A; Peixoto FC; Camargos AF
    Contraception; 2006 Dec; 74(6):446-50. PubMed ID: 17157100
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives.
    Seeger JD; Loughlin J; Eng PM; Clifford CR; Cutone J; Walker AM
    Obstet Gynecol; 2007 Sep; 110(3):587-93. PubMed ID: 17766604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse mood effects during postmenopausal hormone treatment in relation to personality traits.
    Björn I; Bäckström T; Lalos A; Sundström-Poromaa I
    Climacteric; 2006 Aug; 9(4):290-7. PubMed ID: 16857659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of venous thromboembolism in young Swedish women and possibly preventable cases among combined oral contraceptive users.
    Samuelsson E; Hägg S
    Acta Obstet Gynecol Scand; 2004 Jul; 83(7):674-81. PubMed ID: 15225194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. YAZ and the novel progestin drospirenone.
    Mishell DR
    J Reprod Med; 2008 Sep; 53(9 Suppl):721-8. PubMed ID: 18980044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in prescription rates and odds ratios of antidepressant drugs in relation to individual hormonal contraceptives: a nationwide population-based study with age-specific analyses.
    Lindberg M; Foldemo A; Josefsson A; Wiréhn AB
    Eur J Contracept Reprod Health Care; 2012 Apr; 17(2):106-18. PubMed ID: 22385398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The contraceptive vaginal ring compared with the combined oral contraceptive pill: a comprehensive review of randomized controlled trials.
    Roumen FJ
    Contraception; 2007 Jun; 75(6):420-9. PubMed ID: 17519147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol.
    Greco T; Graham CA; Bancroft J; Tanner A; Doll HA
    Contraception; 2007 Jul; 76(1):8-17. PubMed ID: 17586130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany.
    Vree ML; Schmidt J
    Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):108-14. PubMed ID: 11518448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Emotional changes under oral contraceptives].
    Prill HJ; Heister R
    Med Klin; 1971 Feb; 66(6):192-4. PubMed ID: 5279036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of oral contraceptives on well-being and sexuality.
    Bancroft J; Sartorius N
    Oxf Rev Reprod Biol; 1990; 12():57-92. PubMed ID: 2075004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of low-dose combined oral contraceptives and protein S K196E mutation on anticoagulation factors: a prospective observational study.
    Miyoshi T; Oku H; Asahara S; Okamoto A; Kokame K; Nakai M; Nishimura K; Otsuka F; Higashiyama A; Yoshimatsu J; Miyata T
    Int J Hematol; 2019 Jun; 109(6):641-649. PubMed ID: 30891674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.